表皮生长因子受体—酪氨酸激酶抑制剂联合恩度治疗EGFR突变阳性晚期肺腺癌患者的疗效与安全性分析

The clinical effect and safety of EGFR-TKIs combined with endostar on EGFR-mutant advanced lung adenocarcinoma

目的:探讨表皮生长因子受体—酪氨酸激酶抑制剂(EGFR-TKIs)联合恩度治疗EGFR突变阳性晚期肺腺癌患者的临床疗效与安全性。方法:回顾性分析2014年1月至2015年12月在湖南省第二人民医院住院治疗的EGFR突变阳性晚期肺腺癌患者139例,根据患者接受治疗方式的不同分为EGFR-TKIs治疗组(A组,n=71)和EGFR-TKIs联合恩度治疗组(B组,n=68)。比较两组患者的临床疗效、生活质量及不良反应发生率。结果:B组的客观缓解率(ORR)、疾病控制率(DCR)、部分缓解(PR)率均高于A组,差异均有统计学意义(均P<0.05)。B组治疗后生活质量总有效率(86.8%)高于A组(73.2%)(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:EGFR-TKIs联合恩度治疗EGFR突变阳性晚期肺腺癌患者疗效较好,可明显改善患者ORR和DCR,提升患者生活质量,且不增加药物毒性作用。

Objective:To study the clinical effect and safety of epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKIs)combined with endostar in the treatment of EGFR-mutant advanced lung adenocarcinoma.Methods:We retrospectively analyzed139advanced lung adenocarcinoma patients treated in our hospital from Jan.2014to Dec.2015,and were randomized into two groups:group A(EGFR-TKIs)and group B(EGFR-TKIs in combination with endostar).The clinical effect,life quality and toxicity were observed and compared.Results:The objective remission rate(ORR),disease control rate(DCR)and partial remission(PR)rate of group B were significantly higher than those in group A(P<0.05).The total response rate of life quality in group B(86.8%)was higher than that in group A(73.2%)(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:EGFR-TKIs combined with endostar achieved a better clinical effect in the treatment of EGFR-mutant advanced lung adenocarcinoma.This combination could improve the life quality of patients,and did not increase adverse reactions.